3D Systems Announces Establishment of Medical Advisory Board & Appointment of Dr. Stephen K. Klasko as Chair
ROCK HILL, S.C., May 16, 2022 (GLOBE NEWSWIRE) -- Today, (NYSE:DDD) announced the formation of the company’s first Medical Advisory Board (MAB) and the appointment of Stephen K. Klasko, MD, MBA as Chair. The primary mission of the MAB will be to provide strategic input, guidance, and recommendations for the company’s emerging regenerative medicine efforts as they begin moving from research into advanced development and, ultimately, into human application. The MAB will comprise a diverse spectrum of skill sets and experiences ranging from scientific expertise to commercial application, including advising on the formation of key partnerships to reduce program risks and accelerate the attainment of program objectives.
Dr. Klasko, who will serve as the MAB’s first Chair, is one of the most respected executives in the healthcare industry today, known for bridging the entrepreneurial mindset of Silicon Valley with the current healthcare ecosystem. Most recently, he led Jefferson Health to become one of the fastest-growing academic health centers in the United States, as president and CEO of Thomas Jefferson University and Jefferson Health. Over Dr. Klasko’s eight-year tenure, Jefferson grew from roughly $1 billion in revenue to over $9 billion, dramatically expanding the institution’s capabilities and reach - establishing one of the nation’s largest and most advanced telemedicine faculty-based healthcare to bring healthcare to millions in need.
Over the course of his accomplished career, Dr. Klasko has served as Dean of two medical schools and CEO of three health systems. He is deeply committed to transforming health care from its traditional focus on “sick care,” to a resilient, proactive system of “healthcare at any address” – designed to bend the cost curve through innovation, make quality care more accessible, and move population health, social determinants, and predictive analytics from philosophic exercises to the mainstream of clinical care and payment models. Dr. Klasko is one of the leading voices in the nation, championing the transformation of healthcare systems in partnership with digital technology innovators in the quest for a very different and brighter future.
Commenting on the creation of the MAB and Dr. Klasko's appointment, Dr. Jeffrey Graves, president and CEO, 3D Systems, commented, "This is a pivotal time in our company’s history where each day we can see more clearly the potential of regenerative medicine to positively impact humanity and the key role our bioprinting technology can play in the future of humankind. The MAB will provide key input, guidance, and support in making this vision a reality. We are blessed with Dr. Klasko’s willingness to chair this group and help guide its formation and operation. Steve is an inspirational leader who articulates a compelling vision for the healthcare industry, including the transformational potential of medical technology to improve patient outcomes, expand access, and reduce medical costs. He embodies a deep passion for entrepreneurism and inclusiveness that has yielded remarkable results throughout his career. In recognition of his accomplishments, in 2020 he was named by the World Economic Forum as their first Distinguished Fellow, in which he has provided key insights to business and political leaders on the future of healthcare and the digital economy in their annual meetings held in Davos, Switzerland. Under Steve's leadership, we look forward to expanding the MAB in the future as our efforts continue to gain momentum."
In addition to authoring five books, numerous articles, and blogs, Dr. Klasko’s track record of visionary leadership has been widely recognized over the course of his career, including his designation as #2 on Modern Healthcare’s “100 Most Influential Individuals,” Fast Company's Most Creative People in Business, Ernst & Young’s “Entrepreneur of the Year” in 2018, and Becker’s Hospital Review’s “100 Great Leaders in Healthcare."
Since he retired from Jefferson Health earlier this year, Dr. Klasko has assumed the role of Executive in Residence for General Catalyst where he is putting into action the "health assurance" model based on the book he wrote with Hemant Taneja, managing partner of GC, entitled "UnHealthcare: A Manifesto for Health Assurance." Since 2008, Dr. Klasko has also been a director of Teleflex (NYSE:TFX) where he has served on both the governance and audit committees.
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "believes," "belief," "expects," "may," "will," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings "Forward-Looking Statements" and "Risk Factors" in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or revise any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law.
About 3D Systems
More than 30 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading additive manufacturing solutions partner, we bring innovation, performance, and reliability to every interaction - empowering our customers to create products and business models never before possible. Thanks to our unique offering of hardware, software, materials, and services, each application-specific solution is powered by the expertise of our application engineers who collaborate with customers to transform how they deliver their products and services. 3D Systems’ solutions address a variety of advanced applications in healthcare and industrial markets such as medical and dental, aerospace & defense, automotive, and durable goods. More information on the company is available at .
A photo accompanying this announcement is available at